# Effectiveness and Tolerability of аgomelatine in the Treatment of Patients With Depression After SARS-CoV-2 (TELESPHOR)

> **NCT05323994** · — · COMPLETED · sponsor: **Servier Russia** · enrollment: 104 (actual)

## Conditions studied

- Depression
- COVID-19

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05323994
- **Lead sponsor:** Servier Russia
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-19
- **Primary completion:** 2023-02-20
- **Final completion:** 2023-03-15
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05323994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05323994, "Effectiveness and Tolerability of аgomelatine in the Treatment of Patients With Depression After SARS-CoV-2 (TELESPHOR)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05323994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*